PDF
Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
Organization: United States Centers for Disease Control (CDC)Published: 2022
"Among presumed immunocompromised persons aged ≥12 years, local and systemic reactions were less frequently reported to v-safe after mRNA booster (dose 4) than after primary series dose 3. Immunocompromised persons aged ≥12 years should receive a first booster ≥3 months after a 3-dose primary COVID-19 vaccination series and a second booster ≥4 months after the first booster." - Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
Additional Authors : Deborah Thompson, John R. Su, Tanya R. Myers, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Product Type: Report
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Adverse Events Following Immunization (AEFI),Monitoring and Surveillance,Vaccine Monitoring and Surveillance,Vaccine Monitoring,Outbreaks and Pandemics,COVID-19 Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Adverse Events Following Immunization (AEFI)
Monitoring and Surveillance
Vaccine Monitoring and Surveillance
Vaccine Monitoring
Outbreaks and Pandemics
COVID-19
Population: Adolescents
Adults
Healthcare Personnel
Region: United States
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.